Showing results (241-250 of 258) with videos related to
Sort By:
Pageof 26
British Journal of Cancer|July 28, 2012
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsU Wagner, C Marth, R Largillier, et al.Oncogene|April 26, 2011
Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancerD Reimer, M Hubalek, H Kiefel, et al.Environmental Science & Technology|February 17, 2010
Arsenic mobilization in a seawater inundated acid sulfate soilScott G Johnston, Annabelle F Keene, Edward D Burton, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)B M Volgger, G H Windbichler, A G Zeimet, et al.Oncogene|January 27, 2010
Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancerG Hofstetter, A Berger, H Fiegl, et al.British Journal of Cancer|October 20, 2011
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancerG Hofstetter, A Berger, E Schuster, et al.Geburtshilfe Und Frauenheilkunde|October 7, 2014
Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus ConferenceM Hubalek, R Bartsch, M Gnant, et al.The New England Journal of Medicine|February 14, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerMichael Gnant, Brigitte Mlineritsch, Walter Schippinger, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factorsJ McGee, M Bookman, P Harter, et al.Pageof 26